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ABSTRACT
Chemical modification of RNA duplexes can provide
practical advantages for RNA interference (RNAi)
triggering molecules including increased stability,
safety and specificity. The impact of nucleotide
modifications on Dicer processing, RISC loading
and RNAi-mediated mRNA cleavage was
investigated with duplexes  25bp in length.It is
known that dsRNAs  25bp are processed by Dicer
to create classic 19-bp siRNAs with 30-end over-
hangs. We demonstrate that the presence of
minimal modification configurations on longer RNA
duplexes can block Dicer processing and result
in the loading of the full-length guide strand into
RISC with resultant mRNA cleavage at a defined
site.These longer, modified duplexes can be highly
potent gene silencers, with EC50s in the picomolar
concentration range, demonstrating that Dicer pro-
cessing is not required for incorporation into RISC
or potent target silencing.
INTRODUCTION
RNA interference (RNAi) is a cellular process by which
diﬀerent classes of small RNAs regulate gene expression,
silence transposon relocation and coordinate diverse
cellular pathways (1). The ﬁrst demonstrations of RNAi
in mammalian cells utilized 19-bp duplexes with 2-nt
30-end overhangs (‘classical’ siRNA) that were meant to
mimic the natural products of Dicer cleavage of longer
RNA duplexes (2). Two major classes of RNA duplexes
are in use for achieving RNAi-mediated silencing for
research and therapeutic applications: ‘classical’ 19-bp
siRNAs, and longer duplexes typically in the range of
25–27-bp (3,4). Chemical modiﬁcation of both types of
RNA duplex is important for many aspects of therapeutic
RNA compound optimization including the prevention of
oﬀ-target eﬀects, reduction of immune stimulation and
increased serum stability (5–8). While there have been
both in vitro and cellular mechanism of action studies
examining classical siRNAs (9), little has been reported
for chemically modiﬁed duplexes with both approaches.
Some of the current models of RNAi action with exog-
enous double-stranded (ds) RNA duplexes include
assumptions with regard to duplex length, requirement
for activity of the RNAse III-class endonuclease Dicer,
and the involvement of accessory proteins in loading the
duplex into the RNA induced silencing complex (RISC).
In fact, Dicer substrate RNA duplexes have been reported
to have dramatically increased gene silencing activity (4).
However, it is unclear whether this can be attributed to the
sequence of the processed duplex or a characteristic of the
original length. Furthermore, a role has been proposed for
Dicer in increasing the eﬃciency of incorporation of RNA
duplexes into the RISC by association with the Argonaute
(Ago) proteins (4,5). In mammalian cells, only the Ago2
protein has slicer activity resulting in cleavage and elimi-
nation of mRNA transcripts (10). Other Ago family
members repress translation of message and may be
responsible for activities characteristic of microRNA
(miRNA) mediated gene silencing (10). While Ago2 is
required for endonucleolytic RISC mediated gene
silencing in mammalian cells, it is less clear if Dicer
plays a necessary role in this process (11). For example,
cells that lack the Dicer enzyme still support eﬃcient gene
silencing by RNAi at levels equal to that of Dicer-
expressing cells (12).
To explore the mechanism of action of chemically
modiﬁed duplexes in the RNAi pathway, we studied
several 25–27-bp dsRNAs with potent silencing activity.
Several aspects of the RNAi mechanism were examined
using a chemical modiﬁcation pattern that did not
decrease silencing ability. We show that the guide
strands of these longer duplexes are able to load into the
RNAi machinery without being processed by the Dicer
enzyme. Our results illustrate that not only is Dicer
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Single-stranded (ss) RNA was synthesized by Integrated
DNA Technologies (Coralville, Iowa) or Thermo
Scientiﬁc Dharmacon RNAi technologies (Lafayette,
Colorado). RNA duplexes were formed by mixing equal
molar ratios of the passenger and guide strands and
incubating at 90 C for 1min followed by 37 C for 1h
(2). All ssRNA and RNA duplexes were stored at
 20 C. See Supplementary Tables S1 and S2 for RNA
sequence information.
Dose response transfections
HEK293 cells (ATCC, Manassas, Virginia) were cultured
in Dulbecco’s Modiﬁed Eagle Media (DMEM) with 10%
Fetal Bovine Serum and 1% Penicillin–Streptomycin.
NIH3T3 Cells (ATCC, Manassas, Virginia) were
cultured in DMEM with 10% Bovine Calf Serum and
1% Penicillin–Streptomycin. All cells were incubated at
37 C with 10% CO2 as recommended by ATCC.
Cultured cells were reverse-transfected with 25nM total
RNA duplex containing 0.005–5nM active RNA duplex
using Lipofectamine RNAiMAX (Invitrogen, Carlsbad,
California) transfection reagent as described by the
manufacturer. Transfection complexes were prepared by
adjusting the ﬁnal concentration of total duplex to 25nM
with a non-targeting control duplex. The non-targeting
chemistry and length matched control duplex targets the
luciferase gene. Transfections were performed in 96-well
plates with media containing no antibiotics and were
incubated for 48h under normal growth conditions.
Cells were lysed and target mRNA (SOD1) was
measured using the QuantiGene bDNA hybridization
assay and gene speciﬁc probes (Panomics, Freemont,
California) using assay conditions described by the man-
ufacturer. The PPIB gene was used as a housekeeping
control to normalize the SOD1 expression since it is not
aﬀected by SOD1 silencing. The percent silencing and
EC50 values were based on comparing the normalized
values of the samples transfected with SOD1 dsRNA to
that of the normalized expression of SOD1 for the
non-targeting control duplex. For duplexes targeting the
PPIB gene, calculations were carried out similarly to
SOD1 targeting duplexes by using the SOD1 gene to nor-
malize expression. The values for EC50 analysis were
calculated and graphically displayed using KaleidaGraph
(Synergy Software, Reading, Pennsylvania).
Argonaute-2 immunoprecipitation and extraction of
complexed RNA from RISC
RNA duplexes were annealed as described and transfected
into 293T cells stably expressing c-myc Ago2 (Hannon
Lab, Cold Spring Harbor Labs, Cold Spring Harbor,
New York) (9). 293T cells were cultured as described
above in the presence of 0.5mg/ml G418 to selectively
express c-myc Ago2. Transfection of RNA duplexes was
carried out using Lipofectamine RNAiMAX (Invitrogen,
Carlsbad, California) in a 10cm plate as described by the
manufacturer. The cells were transfected in media contain-
ing no antibiotics and having a ﬁnal concentration of
RNA duplex of 25nM as described above. Cells were
incubated for 48h before harvesting and immunopre-
cipitation (IP) of c-myc Ago2. Cell harvest and IP was
performed as previously described (9,13). Cells were col-
lected from plates and washed once with 1  PBS and once
in 2ml of hypotonic lysis buﬀer (HLB) [10mM Tris pH
7.5, 10mM KCl, 2mM MgCl2, 5mM DTT and
EDTA-free complete protease inhibitor cocktail (Roche,
Basel, Switzerland)]. Cells were then reconstituted in
0.5ml of HLB and allowed to swell on ice for 15min.
A fraction of the cell lysate (50ml) was taken and added
to 200ml Trizol (Invitrogen, Carlsbad, California) for sub-
sequent gene silencing assays using the QuantiGene
bDNA hybridization assay (Panomics, Freemont,
California). The remainder of the cell lysate was added
to a 1ml Dounce homogenizer with a tight pestle and
cells were homogenized for 30 strokes on ice. Cell lysates
were clariﬁed by centrifugation (14000r.p.m., 30min at
4 C) and supernatant was transferred to a new tube.
One milliliter LB650 buﬀer (0.5% NP40, 150mM NaCl,
2mM MgCl2, 2mM CaCl2, 20mM Tris pH 7.5, 5mM
DTT, 650mM KCl and EDTA-free complete protease
inhibitor cocktail) was added to supernatant or cytosolic
fraction. Anti-c-myc antibody conjugated to agarose
beads (Sigma, St. Louis, Missouri) was added to each
tube and the tubes were incubated overnight at 4 C
while rotating. After overnight incubation, IP reactions
were centrifuged for 2min at 3000r.p.m. and then beads
were washed three times in LB650 buﬀer. After washing
the beads, 200ml of Trizol reagent was added to disasso-
ciate the RNA from the antibody captured Ago2. RNA
was precipitated as described by manufacturer instruc-
tions forgoing an ethanol wash. RNA was reconstituted
in 20ml of TE buﬀer (10mM Tris–HCl, 1mM EDTA).
Northern blot of RNA captured from Ago2
immunoprecipitation
RNA was analyzed on a 15% polyacrylamide, TBE–urea
denaturing gel.
32P-end size makers ranging from
21 to 25nt (see Supplementary Table S3 for sequences)
were included on the gel to determine the size of the
captured RNA. The RNA was transferred to a nylon
membrane and UV cross-linked. The membrane was
pre-hybridized using UltraHyb-Oligo Buﬀer (Ambion,
Austin, Texas) for 30min at 42 C and then
32P-labeled
DNA / locked nucleic acid probes complementary to the
guide strand were added to the hybridization buﬀer. After
overnight incubation at 42 C, the membrane was washed
twice for 30min in wash buﬀer (1 SSC buﬀer, 0.1%
SDS). The blot was visualized by exposing to BioMAX
autoradiography ﬁlm (Kodak, Eastham, New York).
Film was developed using an automatic ﬁlm processing
unit.
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293T cells expressing c-myc Ago2 were transfected with
RNA duplexes and Ago2 was immunoprecipitated as
described above. After the ﬁnal wash, the agarose beads
containing Ago2 complexes loaded with transfected
RNAs were re-constituted in 10ml buﬀer (100mM KCl,
2mM MgCl2 and 10mM Tris pH 7.5). A synthetic RNA
identical to a 50-nt region of the human SOD1 gene
(see Supplementary 3 for sequence) containing the target
site for the transfected 25-bp duplexes or 19-bp+2-nt
siRNAs was
32P-50-end labeled and gel puriﬁed. The syn-
thetic substrate was designed speciﬁcally to have base 21
correspond to position 10 of the guide strand of the
19-bp+2-nt siRNA or 25-bp duplex. For the cleavage
reaction, the reconstituted IP reaction (10ml) was added
to 4ml of labeled synthetic substrate, 1ml RNAsin
(Promega, Madison, Wisconsin) and 5ml buﬀer (100mM
KCl, 2mM MgCl2 and 10mM Tris pH 7.5) for a ﬁnal
volume of 20ml. The reaction was incubated for 2h at
30 C. After incubation, the reactions were anlayzed on a
15% polyacrylamide, TBE–urea denaturing gel. The gel
was exposed to autoradiography ﬁlm as above. Size of
cleavage product was determined by comparison to
32P-labeled size marker RNAs.
Dicer processing assay
RNA duplexes were incubated with recombinant human
Dicer enzyme (Genlantis, San Diego, California)
according to manufacturer recommendations and
previously described conditions (4). Samples were
incubated overnight ( 16h) at 37 C with and without
Dicer enzyme. Reactions were stopped by the addition
of TBE gel loading buﬀer and snap frozen in liquid
nitrogen. A fraction (16pmol) of the sample was
analyzed on a native, TBE buﬀered, 20% polyacrylamide
gel. An siRNA marker (New England Biolabs, Ipswich,
Massachusetts) was included on the gel. The gel was
stained using SYBR green II (Invitrogen, Carlsbad,
California) for 20min and then visualized using a UV
transluminator and CCD camera. UV images and
relative quantiﬁcation analysis were carried out using the
UVP BioChemi imaging station with LabWorks software
(UVP, Upland, California).
Generation of 100-bp dsRNA
The template for in vitro transcription to generate the
100-bp RNA was derived by high ﬁdelity PCR ampliﬁca-
tion (Roche, Indianapolis, Indiana) of a mouse SOD1
cDNA clone (Accession number: BC048874) (Origene,
Rockville, Maryland). The forward (TAATACGACTCA
CTATAGGGCGTGTGATCTCACTCT) and reverse
(TAATACGACTCACTATAGGGTACTTTCTTCATTT
CCACCTTTGC) primers (Integrated DNA Technologies,
Coralville, Iowa) incorporate a T7 promoter on both
strands. The PCR fragment was puriﬁed using a
QIAquick PCR Puriﬁcation Kit (Qiagen, Valencia,
California) and the size was veriﬁed on an agarose gel.
The in vitro transcription and puriﬁcation of the 100-bp
dsRNA was performed using the MEGAscript RNAi Kit
(Ambion/Applied Biosystems, Austin, Texas) according
to manufacturer’s instructions.
Dicer null cell transfections
Mouse derived embryonic stem cells that are homozygous
null or heterozygous for the enzyme Dicer were generated
by Murchison and co-workers and cultured as previously
described (12). Dose response transfections were carried
out by adapting previously described conditions (14) to a
96-well dose response method described above. Active
RNA duplexes targeting the human SOD1 gene that had
100% homology to mouse SOD1 were transfected in con-
centrations ranging from 0.05 to 10nM in a ﬁnal RNA
concentration of 25nM using RISC-free ﬁller RNA
(Dharmacon, Lafayette, Colorado). Cells were incubated
for 48h after transfection and mRNA levels were
measured using the QuantiGene bDNA hybridization
assay (Panomics, Freemont, California) as described
above.
RESULTS
Modiﬁed RNA duplexes demonstrate potent RNAi activity
To explore how chemical modiﬁcations would aﬀect
RNAi activity we created a panel of 25-bp duplexes with
several modiﬁcation patterns and measured their ability to
silence the superoxide dismutase gene (SOD1) (data not
shown). We identiﬁed modiﬁcation schemes that main-
tained eﬃcient gene silencing when compared to an
unmodiﬁed duplex. One such pattern consists of four
20OMe modiﬁcations on both ends of the passenger
strand with the guide strand left unmodiﬁed, referred to
throughout as modiﬁcation pattern ‘4/4’ (Figure 1A).
Target mRNA levels were determined following
transfection of human HEK293 cells with 19-bp+2-nt
30-end overhang (19-bp+2-nt siRNA) and blunt-ended
25-bp duplex RNA either unmodiﬁed or with 4/4 20OMe
modiﬁcation (Figure 1B). The EC50 (eﬀective concentra-
tion required to induce a 50% eﬀect) of the 25-bp modiﬁed
RNA duplex was in the picomolar concentration range
and equivalent to the silencing activity of the unmodiﬁed
25-bp duplex or 19-bp+2-nt siRNA of the same
sequence. This result is not sequence speciﬁc, potent
activity is also observed when comparing modiﬁed and
unmodiﬁed duplexes targeting other sites in SOD1 (data
not shown). Furthermore, picomolar inhibition was also
achieved by targeting the cyclophillin B (PPIB) gene in
HEK293 cells with a 25bp modiﬁed RNA duplex at a
known site for gene silencing activity (Figure 1C). Gene
silencing with these duplexes is not speciﬁc to human cells
as similar potency is observed in murine (NIH3T3)
cells (Supplementary Figure S1). Overall, we have
identiﬁed duplexes with potency in the picomolar range
for over 10 genes and at multiple sites per gene (data
not shown).
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To elucidate how chemical modiﬁcations would alter how
the duplexes interacted with the RNAi machinery we
immunoprecipitated the associated guide strand in
Ago2:RISC to determine its actual length. These experi-
ments were performed by introducing 25-bp RNA
duplexes into 293T cells stably expressing c-myc
Ago2:RISC. Immunoprecipitation of c-myc-Ago2:RISC
was carried out followed by extraction of RNA bound
to the protein complexes. The RNA was analyzed by
northern blotting using a probe complementary to the
guide strand of the duplex (Figure 2A). By comparison
to ssRNA markers of 21–25nt, the Ago2:RISC-associated
guide strand of the two tested 25-bp duplexes was deter-
mined to be 25-nt in length. These data conﬁrm that the
guide strand is bound by Ago2:RISC in its full length
form. Unexpectedly, the unmodiﬁed 25-bp duplex was
not eﬃciently cleaved to the expected smaller product
that would have resulted from eﬃcient Dicer processing
in the cell. We conﬁrmed that Dicer products can be
detected in this assay using an unmodiﬁed 27-bp duplex
(Supplementary Figure S3A). In this case, a guide strand
of  21-nt is shown to be associated with Ago2:RISC. We
hypothesize that since this engineered 293T cell line dra-
matically over-expresses c-myc tagged Ago2 protein the
longer duplex interacts with the Ago2:RISC complex
before Dicer processing. Furthermore, it is possible that
there is a sequence speciﬁc event that causes this RNA
duplex to have a greater aﬃnity for RISC. Potent silencing
activity was conﬁrmed in this 293 cell line by measuring
target mRNA reduction in an aliquot of the cell
lysate prior to immunoprecipitation (Figure 2B and
Figure 1. Activity comparison of unmodiﬁed and modiﬁed 25-bp RNA duplexes. (A) Sequence and modiﬁcation pattern of SOD1 targeted RNA
duplexes. R, RNA nucleotide; M, 20OMe modiﬁed nucleotide; PS, passenger strand; GS, guide strand. Standard nomenclature, e.g. 4/4, used
throughout represents the number of 20OMe nucleotides on the 50 and 30 ends of a particular strand, respectively. Nucleotide modiﬁcations are
placed on the passenger strand unless otherwise noted. (B) HEK293 (human) cells were transfected with a 19-bp+2-nt siRNA (ﬁlled circle), an
unmodiﬁed, 25-bp, blunt-ended duplex (ﬁlled square), or a 25-bp, blunt-ended duplex with 4/4 20OMe PS modiﬁcations (open square). The RNA
duplexes target the SOD1 gene in a region that is homologous in human and murine cells. Cells were lysed 48h after transfection and mRNA levels
were measured using a bDNA hybridization assay as described in ‘Materials and Methods’ section. The EC50 values for the 19-bp+2-nt siRNA,
unmodiﬁed 25-bp duplex and 4/4 20OMe 25-bp duplex are 0.037±0.004, 0.037±0.004 and 0.053±0.005nM, respectively. Percent SOD1 mRNA
reduction was calculated as described in ‘Materials and Methods’ section. (C) Dose response transfection of HEK293 cells with RNA duplexes with
the same seed region targeting the PPIB gene. The EC50 values for the 19-bp+2-nt siRNA (ﬁlled circle), 4/4 20OMe 25-bp duplex (open square),
and 4/4 20OMe 27-bp duplex (open triangle) are 0.045±0.026, 0.027±0.014 and 0.075±0.049nM, respectively. Percent PPIB mRNA reduction
was calculated using the SOD1 expression level for normalization.
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to show that the full-length, unprocessed guide strand of a
modiﬁed 26-bp duplex is also loaded into Ago2:RISC
(Supplementary Figure S2).
Chemically modiﬁed RNA duplexes cleave the mRNA
target at a deﬁned position
Further characterization of the mechanism of action of a
modiﬁed 25-bp duplex was carried out to determine the
cleavage position(s) in the target sequence. It has been
previously shown that classical siRNA will direct
cleavage across from nucleotides 10 and 11 in reference
to the 50-end of the guide strand (9,15). There are two
methods that are well suited to elucidate the position of
mRNA target cleavage: 50 RACE PCR and an in vitro
cleavage assay with immunopuriﬁed RISC on deﬁned
substrates. We chose to use immunopuriﬁed RISC to
directly determine the nucleotide position of the cleavage




RNA was designed to mimic the target site of these
active duplexes (Figure 3A). For the classical, 19-bp
siRNA duplex, cleavage at the expected site in this syn-
thetic substrate generates a 21-nt end-labeled product.
One chemically modiﬁed 25-bp duplex (c) was designed
to have the same 50-end as the siRNA; the other 25-bp
duplex sequence is shifted by 4nt (d). After transfection
with the duplexes described above, Ago2 complexes were
generated by immunoprecipitation (as described in
Figure 2). The immunoprecipitates were incubated with
the labeled synthetic substrate and the resultant cleavage
products are shown in Figure 3B. The 25-bp duplexes (b
and c) give rise to products that are the same size as the
19-bp+2-nt siRNA (a), conﬁrming that target cleavage
occurs across from positions 10 and 11 relative to the
50-end of the guide strand in Ago2. Re-positioning of
10nt by using a targeting duplex with a diﬀerent start
position results in a concomitant shift in the cleavage site
(as shown with duplex d) (Figure 3A). The result was con-
ﬁrmedwiththreeotherduplexesdesignedtodirectcleavage
in a diﬀerent region of the SOD1 gene (Supplementary
Figure S4). These results conﬁrm that the position of the
target cleavage site is deﬁned by the 50-end of the guide
strand for RNA duplexes that are >19-bp in length.
Chemical modiﬁcations prevent Dicer processing
The above studies show that modiﬁed 25-bp RNA
duplexes are able to achieve potent gene silencing, load
Figure 2. Northern blot detection of transfected RNA in Ago2. 293T
cells expressing c-myc Ago2 were transfected with various duplexes that
target the same area in SOD1. The cells were harvested, lysed, and
c-myc Ago2 and associated RNA was immunoprecipitated as described
in ‘Materials and Methods’ section. After immunoprecipitation, the
RNA from the IP fractions was extracted and precipitated. RNA was
loaded onto a denaturing polyacrylamide gel, transferred to a nylon
membrane, and detected using a LNA probe speciﬁc to the guide
strands of the transfected RNA duplexes. (A) Northern blot of the
guide strand of SOD1 targeting RNA duplexes. ssRNA size markers
21–25-nt long (designated by underline) were included in lanes adjacent
to the captured guide strand RNA (lanes: 21, 0/0; 25, 0/0; and 25, 4/4).
(B) Expression of SOD1 after transfection of 293T cells expressing
c-myc Ago2. Before immunoprecipitation of c-myc Ago2 a fraction
of the cell lysate was taken for total cell RNA puriﬁcation. The
RNA was puriﬁed and gene expression was measured using a bDNA
assay as described in ‘Materials and Methods’ section.
Figure 3. Modiﬁed RNA duplex (25bp) cleaves target mRNA adjacent
to positions 10–11 of the guide strand. (A) Schematic of the
32P-labeled
synthetic substrate, predicted cleavage positions and
32P-labeled resul-
tant products. (B) RNA duplexes targeting SOD1 were transfected into
293 cells expressing c-myc Ago2 and prepared as described in
‘Materials and Methods’ section for the in vitro cleavage reaction.
Samples (a–e) were loaded onto a denaturing, polyacrylamide gel
along with single-stranded RNA size markers of 21 and 25nt and the
full-length substrate (designated by underlines). Lanes a–e correspond
to treatment with the following duplexes as shown in Figure 3A. a,
unmodiﬁed 19-bp+2-nt siRNA; b, 0/0 25-bp duplex; c, 4/4 20OMe
25-bp duplex; d, 4/4 20OMe 25-bp duplex, shifted 4nt compared with
b and c; e, Luciferase control duplex. Denaturation conditions were
applied to the samples when running the PAGE, however, there
seems to be a very strong interaction between actively targeting
Ago2:RISC and the synthetic substrate (compared to lane e that does
not target the synthetic substrate) which results in a band larger than
the 50-nt substrate alone.
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a deﬁned site. It has been shown that methylation of
nucleic acids can prevent endonuclease activity (16) and
we reasoned that the modiﬁcations employed in our
duplexes would inhibit Dicer’s ability to process
duplexes >21-bp. To explore Dicer processing with these
chemically modiﬁed RNA duplexes, a panel of modiﬁca-
tion conﬁgurations was tested for susceptibility to Dicer
cleavage in vitro (Figure 4A). Since activity and target
speciﬁcity are deﬁned by the 50 position of the guide
strand sequence or ‘seed region’ that is loaded into
RISC (17), an understanding of processed products, if
any, would help elucidate the role of Dicer processing in
RNAi activity. A series of duplexes targeting the SOD1
gene were modiﬁed on both ends (50 and 30) of the passen-
ger strand with varying numbers of 20OMe nucleotides.
These duplexes were incubated with recombinant human
Dicer enzyme and analyzed for processing (Figure 4B).
The unmodiﬁed 25-bp duplex and the duplex with one
20OMe modiﬁcation on both ends of the passenger
strand (1/1) are completely processed to the 21-bp
siRNA product. The duplex with two 20OMe on both
ends of the passenger strand (2/2) showed partial process-
ing under these conditions (16h incubation) with  70% of
the duplex remaining unprocessed in this study
(Figure 4C). However, the duplex with either three or
four 20OMe modiﬁed nucleotides on both ends of the pas-
senger strand (3/3 or 4/4) was not processed by the Dicer
enzyme.
Dicer processing of this same SOD1 targeting duplex
sequence bearing additional modiﬁcation conﬁgurations
was explored. It has been reported that the presence of a
blocking group on the 30-ends of both strands of a Dicer
substrate can block processing (4). Additional conﬁgura-
tions tested included four 20OMe modiﬁcations on both
50-ends, both 30-ends, or both ends (50 and 30) of each
individual strand of the duplex (passenger or guide
strand). Dicer processing is blocked by all of these modi-
ﬁcation patterns (Figure 4D). Similar results are obtained
with 20OMe modiﬁed 25-bp duplexes targeting a diﬀerent
sequence in the SOD1 gene (Supplementary Figure S5).
Dicer enzyme is not required for RNAi with duplexes
greater than 21bp
For a more direct test of the role of Dicer in RNAi, longer
synthetic duplexes were tested for target gene silencing
in a mouse embryonic stem cell line deﬁcient for the
Dicer enzyme (12). Dicer homozygous null ( / )o r
heterozygous (+/ ) mutant cells were transfected with
RNA duplexes and reduction of the target mRNA was
quantiﬁed. Previously published data showed that classi-
cal siRNA duplexes eﬃciently silence target genes in the
absence of Dicer and that pre-miRNAs are unable to form
mature miRNAs which are a requirement for RISC rec-
ognition and occupancy (12,18,19). We performed EC50
analyses with duplexes increasing in length and assessed
their ability to silence endogenous SOD1 in the Dicer null
Figure 4. 20OMe modiﬁcations inhibit Dicer enzyme processing of RNA duplexes into siRNA. (A) Schematic of chemical modiﬁcations included in
the RNA duplexes that target SOD1. R, RNA nucleotide; M, 20OMe modiﬁed nucleotide; PS, passenger strand; GS, guide strand. Nucleotide
modiﬁcations are placed on the passenger strand unless otherwise noted. (B) RNA duplexes were incubated overnight with recombinant human Dicer
enzyme (+) or buﬀer ( ) and products were run on non-denaturing polyacrylamide gel and visualized as described in ‘Materials and Methods’
section. Lane M designates siRNA duplex markers with sizes of 25, 21 and 17-bp (top to bottom). (C) Products resulting from incubation of RNA
duplexes with additional combinations of 20OMe modiﬁcations with Dicer (+) or buﬀer ( ) as described above and in ‘Materials and Methods’
section. The siRNA duplex size markers (M) are as in Figure 4A. (D) Quantitation of processing of 25-bp RNA duplex with 2/2 20OMe chemistry,
panel B. Density of the partially processed bands was quantiﬁed using LabWorks software.
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with previous reports (12) and suggest that although
longer RNAs can associate with Ago2 in the Dicer null
cells, there appears to be a loss in eﬃcacy when the RNA
duplex is >39-bp. The EC50 value doubles with a 41-bp
duplex in the Dicer null cells when compared to the Dicer
heterozygous cells. 100-bp duplexes silenced eﬀectively in
Dicer (+/ ) cells but in the Dicer ( / ) cells there was
extensive cell death at 24h and there were no healthy
adherent cells by 48h after transfection making it
impossible to accurately measure silencing activity
(Supplementary Figure S7). These data support the bio-
chemical results presented above showing that long, chem-
ically modiﬁed duplexes are able to eﬃciently silence in the
absence of Dicer (Figure 5B).
DISCUSSION
Chemical modiﬁcation of RNAi duplexes has been
demonstrated to impart novel properties that have
beneﬁts for eﬃcacy in vivo and for therapeutic applica-
tions. The 20OMe RNA nucleotide is one example of a
chemical modiﬁcation that has been shown to confer
these attributes when applied to RNA duplexes in
speciﬁc conﬁgurations. Incorporation of 20OMe modiﬁca-
tions can dramatically increase nuclease resistance in
serum rich environments as compared to unmodiﬁed
dsRNA (20). Depending on the conﬁguration, as few as
two 20OMe modiﬁcations can prevent immune stimulation
mediated through TLR-7 pathways (7). Jackson and col-
leagues showed that a single 20OMe modiﬁcation in the
guide strand can reduce the number of oﬀ-target eﬀects as
demonstrated through microarray analyses (8). Addition
of 20OMe modiﬁcations to the passenger strand can also
inhibit incorporation of this strand into the Ago2:RISC
thereby reducing oﬀ-target eﬀects. There are two potential
ways that a 20OMe modiﬁcation could block incorpora-
tion into Ago2:RISC; inhibition of phosphorylation and
prevention of interaction with the protein. Liu and col-
leagues have shown that phosphorylation of the 50-end is
required for an RNA strand to interact with Ago2 (9)
since there is a binding site for the phosphate in the
protein’s MID domain (9,10). Furthermore, Nyka ¨ nen
and co-workers demonstrate that 20OMe modiﬁcation of
the 50 most nucleotide blocks phosphorylation activity at
this position (21). The 20OMe modiﬁcation is also
observed to prevent interaction of the passenger strand
with Ago2:RISC when compared to an unmodiﬁed pas-
senger, even when this strand has been exogenously
phosphorylated (Supplementary Figure S6). Since the dis-
covery that long dsRNA is a mediator of RNAi, novel
nucleic acid structures with a large variety of chemical
modiﬁcations and nucleotide conﬁgurations have been
tested for silencing potency as well as other therapeutic
properties. Our studies were designed to address the mech-
anism of action of longer, 20OMe modiﬁed RNA duplexes
in comparison to the extensively investigated mechanism
of action for classical siRNA (9).
Data presented here expand the understanding of how
chemically modiﬁed RNA duplexes interact with key
proteins involved in the silencing pathway. Although
there have been previous mechanism of action studies
looking at Dicer processing in vitro (4,5,22) these studies
further characterize the impact of nucleotide modiﬁcation
on RNAi activity. These investigations probed multiple
aspects of the RNAi mechanism of action such as RISC
loading, cleavage of the target mRNA, activity in the
absence of Dicer, in vitro Dicer enzyme processing and
gene silencing activity. Models have been proposed sug-
gesting that the enzyme Dicer is necessary for, or
enhances, RISC-mediated gene silencing (4). It is
Figure 5. Dicer enzyme is not required for RNAi activity with RNA
duplexes >21-bp. Mouse ES cells that were heterozygous (+/ )o r
homozygous null ( / ) for the Dicer gene were transfected with dif-
ferent RNA duplexes targeting SOD1 or PPIB as described in
‘Materials and Methods’ section. (A) EC50 analysis of unmodiﬁed
RNA duplexes targeting SOD1 ranging from 41 to 21bp in length.
The EC50 values were calculated and generated from a dose response
transfection as described in ‘Materials and Methods’ section. The EC50
values were calculated using RNA duplex concentrations from 0.01 to
10nM; Dicer heterozygous null cells (black squares), Dicer
homozygous null cells (open squares). The EC50 value for the 100-bp
duplex in Dicer homozygous null cells (black X) was not determined
due to signiﬁcant cellular toxicity. (B) PPIB mRNA expression data
for four duplexes are shown (in order); 19-bp+2-nt siRNA
(solid white bar), unmodiﬁed (0/0) 25-bp duplex (solid black bar),
4/4 20OMe 25-bp duplex (dark gray bar) and 4/4 20OMe 27-bp
duplex (light gray bar).
Nucleic Acids Research, 2010,Vol.38, No. 11 3777undisputed that Dicer is required for miRNA and shRNA
processing and is required to trigger RNAi by very long,
RNA duplexes, however, its role in RNAi with exogenous
RNA is still not clear. Dicer acts as a molecular ruler by
cleaving long stretches of RNA duplex into smaller species
of  21-bp in length (23). In the case of the chemical mod-
iﬁcation patterns tested, we show that 20OMe modiﬁca-
tions properly positioned can prevent Dicer processing
of dsRNA that are long enough to serve as a Dicer
substrate, yet these unprocessed RNAs still maintain
silencing potency (Figure 1 and Supplementary Figure
S1). In addition, potency of longer duplexes is maintained
in cells that lack the Dicer enzyme (Figure 5).
Studies by MacRae and colleagues support the ability
of exogenous duplexes to enter the RNAi pathway with no
Dicer requirement as there was no co-association between
Ago2 and Dicer observed when reconstituting RISC
loading in vitro (11). Alternatively, some models do
propose that Dicer transports or loads the RNA duplex
into Ago2:RISC, where passenger strand separation is
directed by a Dicer associated protein or Ago2 itself.
To date, the mechanism of action of RISC loading
remains a subject of examination. It was ﬁrst proposed
by Tomari and colleagues that a protein sensor (Dicer)
carries out helicase activity to disassociate the passenger
strand when associated with Ago2 (24). Further study led
to a second model that strongly suggested that the RNA
duplex is presented into RISC and the passenger strand is
instead cleaved before removal by Ago2 (25). Both mech-
anisms (unwinding or cleavage) may be operative. The
20OMe modiﬁcation, when positioned in certain locations
on the passenger strand, can drastically reduce or abolish
RNAi activity possibly due to the inability of the passen-
ger strand to be dissociated [data not shown and (15,26)].
Several proteins have been implicated in the RISC loading
mechanism of action but are not always in agreement
when comparing in vitro reconstitutions to cell-based
manipulations of the RNAi mechanism or when
comparing studies in diﬀerent organisms (11,12,26–31).
The data presented here demonstrate that Dicer cleavage
activity is not essential for triggering of RNAi activity
with exogenous RNA duplexes although the Dicer
protein may still play a role in RISC loading. It is also
possible that other dsRNA-binding proteins may play a
key role in RISC loading such as the recently reported
TAR RNA-binding protein (TRBP) in mammalian cells
(27,30).
The observation that modiﬁed duplexes not cleaved by
Dicer still function as very potent gene silencers, led us to
investigate other aspects of their interaction with RISC.
Immunoprecipitation of Ago2-associated RNAs allowed
us to establish that the guide strand is loaded into the
Ago2:RISC as a full-length, unprocessed product
(Figure 2 and Supplementary Figures S2 and S3) and
demonstrated that these duplexes are resistant to Dicer
processing (Figure 4 and Supplementary Figure S5).
Interestingly, we identiﬁed one particular 25-bp SOD1 tar-
geting duplex that is eﬃciently processed by the Dicer
enzyme in vitro (Figure 4), but is not processed in the
cells (Figures 2 and 3). This result suggests some
sequence speciﬁc aﬃnity for RNAi-associated proteins
that circumvent Dicer and could have implications for
the mechanism of gene silencing in vivo. Our ﬁndings dem-
onstrate that longer duplexes load into the RISC complex
in a manner which results in a target cleavage position
deﬁned by the 50-end of the RNA guide strand. These
results are consistent with a recent X-ray crystal structure
of an Ago2-nucleotide complex showing that longer guide
strands can be accommodated as well as reports
examining the guide strand/mRNA interaction through
crystal structure and cleavage position analyses (32,33).
RNAi has been shown to be a conserved process that
will require further investigation to deﬁne details of the
full mechanism of action. This study of the RNAi mech-
anism with modiﬁed duplexes demonstrates that there can
be some generalization of the information obtained from
studies with classical 19–21-bp siRNAs. In particular, we
have shed light on the structural features that lead to posi-
tioning of the guide strand in RISC and deﬁnition of the
seed region sequence for longer, chemically modiﬁed RNA
duplexes. These results expand upon the current model of
RNAi induced by synthetic dsRNAs by extending recent
observations regarding Dicer and the active RISC.
Chemical modiﬁcation of dsRNA provides many advan-
tages for the further development of RNAi compounds as
therapeutics and further elucidation of the pathway with
such reagents should enable improved RNA compound
design.
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